Image-guided percutaneous ablation for lung malignancies

Shang, Youlan; Li, Ge; Zhang, Bin; Wu, Ying; Chen, Yanjing; Li, Chang; Zhao, Wei; Li, Jun

doi:10.3389/fonc.2022.1020296

Cited by 6 publications

(5 citation statements)

References 104 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Radiofrequency ablation is a minimally invasive procedure that has been used for more than 30 years in the treatment of various organs including kidney, liver, thyroid, and lung. [65][66][67][68] In 2012, it was approved by the Food and Drug Administration as a treatment for symptomatic ULs. 69 This technology enables the ablation of ULs by inducing coagulative necrosis using ultrasound-guided laparoscopic or transcervical devices.…”

Section: Radiofrequency Ablationmentioning

confidence: 99%

See 1 more Smart Citation

The challenge of FIGO type 3 leiomyomas and infertility: Exploring therapeutic alternatives amidst limited scientific certainties

Favilli,

Mazzon,

Etrusco

et al. 2023

Intl J Gynecology & Obste

View full text Add to dashboard Cite

Uterine leiomyomas (ULs) are non‐cancerous tumors composed of smooth muscle cells that develop within the myometrium and represent the most prevalent pathological condition affecting the female genital tract. Despite the volume of available research, many aspects of ULs remain unresolved, making it a “paradoxical disease” where the increase in available scientific literature has not been matched by an increase in solid evidence for clinical management. Fertility stands at the top of the list of clinical issues where the role of ULs is still unclear. The leiomyoma subclassification system, released by the International Federaion of Gynecology and Obstetrics (FIGO) in 2008, introduced a new and more effective way of categorizing uterine fibroids. The aim was to go beyond the traditional classification “subserosal, intramural and submucosal”, facilitating a detailed examination of individual ULs impact on the female reproductive system. The “type 3 UL” is a special type of myoma, characterized by its complete myometrial development while encroaching the endometrium. It is a unique “hybrid” between a submucous and an intramural UL, that may exert a detrimental “double hit” mechanism, which is of particular interest in patients wishing pregnancy. To date, no robust evidence is available regarding the management of type 3 ULs. The aim of this narrative review is to provide a comprehensive overview of the physiopathological mechanisms that type 3 UL may exert on fertility, and to present new perspectives that may help us to better understand both the need for and the methods of treating this unique type of fibroid.

show abstract

Section: Radiofrequency Ablationmentioning

confidence: 99%

Section: Putative Alternative Surgical Treatments To Hysteroscopymentioning

confidence: 99%

The challenge of FIGO type 3 leiomyomas and infertility: Exploring therapeutic alternatives amidst limited scientific certainties

Favilli,

Mazzon,

Etrusco

et al. 2023

Intl J Gynecology & Obste

View full text Add to dashboard Cite

show abstract

“…The utilization of image‐guided percutaneous lung puncture enables the direct administration of therapeutic drugs into lesion sites. Moreover, this technique enables the successful application of targeted microwave ablation, radiofrequency ablation, laser ablation, cryoablation, and other percutaneous ablation methods (Chu & Dupuy, 2014; Ma et al, 2017; Ni et al, 2021; Shang et al, 2022; Smith & Jennings, 2018). Despite its potential benefits in increasing local drug concentration in tumors and reducing systemic toxicity, this approach is not without limitations.…”

Section: Comparison With Other Existing Techniquesmentioning

confidence: 99%

Pulmonary delivery of nano‐particles for lung cancer diagnosis and therapy: Recent advances and future prospects

Han,

Wang

et al. 2023

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Although our understanding of lung cancer has significantly improved in the past decade, it is still a disease with a high incidence and mortality rate. The key reason is that the efficacy of the therapeutic drugs is limited, mainly due to insufficient doses of drugs delivered to the lungs. To achieve precise lung cancer diagnosis and treatment, nano‐particles (NPs) pulmonary delivery techniques have attracted much attention and facilitate the exploration of the potential of those in inhalable NPs targeting tumor lesions. Since the therapeutic research focusing on pulmonary delivery NPs has rapidly developed and evolved substantially, this review will mainly discuss the current developments of pulmonary delivery NPs for precision lung cancer diagnosis and therapy.This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Respiratory Disease Therapeutic Approaches and Drug Discovery > Emerging Technologies Diagnostic Tools > In Vivo Nanodiagnostics and Imaging

show abstract

“…Local thermal ablation, a precise and minimally invasive technique, may be applied in patients with both early-stage and metastatic NSCLC with tumors ≤3 cm. The advantages of local thermal ablation over open surgery include shorter hospital stays, reduced risks, minimized blood loss, manageable or moderate pain levels, limited impact on lung function and the possibility of repeated treatments ( 9 ). Combining microwave ablation (MWA) with TKI treatment has led to significant improvements in both progression-free survival (PFS) and overall survival (OS) rates for patients with oligometastatic NSCLC.…”

Section: Introductionmentioning

confidence: 99%

Combination of microwave ablation and systemic treatments achieve a long survival time for a patient with metachronous advanced double primary lung and colon adenocarcinoma: A case report

Li,

Xu,

Cai

et al. 2024

Oncol Lett

View full text Add to dashboard Cite

Despite significant improvements that have been made in terms of progression-free survival and overall survival rates brought about by targeted therapy in non-small cell lung cancer (NSCLC), the emergence of drug resistance remains a limiting factor. However, a previous study has shown promising results by combining local microwave ablation (MWA) with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) therapy for patients with oligometastatic NSCLC. The current study presented the case of a Chinese female patient who was identified as having lung adenocarcinoma (LADC) with EGFR exon 19 deletions (Del) in January 2014, and who experienced multiple instances of oligoprogression but showed a positive response to a combination of chemotherapy, MWA and a TKI drug. First, the patient was treated with four cycles of chemotherapy (120 mg docetaxel on day 1 and 40 mg cisplatin on days 1, 2 and 3; every three weeks as one cycle) and gefitinib (Iressa; 250 mg/day), maintaining a partial response for 17 months. In August 2015, a new solitary lesion was identified in the right lung and erlotinib (Tarceva; 150 mg/day) was administered for 3 months thereafter. In response, the patient underwent ablation of both the new right lung lesion and the primary left lung lesion in January 2016. Subsequently, a treatment course consisting of six cycles of chemotherapy (0.8 g pemetrexed on day 1 and 70 mg nedaplatin on days 1 and 2; every three weeks as one cycle) resulted in stable disease. In May 2016, the patient began treatment with osimertinib (AZD9291; 80 mg/day), resulting in a rapid shrinkage of the mediastinal lymph node after one month, which has been providing a benefit for the patient for 82 months and counting. Of note, the patient also developed metachronous colon cancer in January 2020, followed by the identification of right posterior liver metastases in February 2020 and lung metastases in May 2021 and in February 2022. To address this, the patient underwent radical resection of colon cancer and liver metastasectomy and received a combination of chemotherapy with bevacizumab, along with MWA for lung metastases. Remarkably, the patient has achieved long-term survival of 110 months. In conclusion, this case highlights the promising potential of combining MWA with systemic therapy for a patient with advanced LADC harboring EGFR exon 19 Del and metachronous lung and liver-metastasized colon adenocarcinoma. MWA effectively controlled both in situ oligoprogression and new oligoprogression, thereby enhancing the efficacy of systematic chemotherapy/TKI therapy. Furthermore, this case report emphasizes the importance of repeated histologic biopsies and genetic testing as reliable indicators for adjusting treatment regimens. Physicians should also remain vigilant regarding the occurrence of secondary primary carcinomas, and timely and accurate adjustments to treatment plans will be of significant benefit to patients in terms of treatment efficacy and overall quality of life.

show abstract

Image-guided percutaneous ablation for lung malignancies

Cited by 6 publications

References 104 publications

The challenge of FIGO type 3 leiomyomas and infertility: Exploring therapeutic alternatives amidst limited scientific certainties

The challenge of FIGO type 3 leiomyomas and infertility: Exploring therapeutic alternatives amidst limited scientific certainties

Pulmonary delivery of nano‐particles for lung cancer diagnosis and therapy: Recent advances and future prospects

Combination of microwave ablation and systemic treatments achieve a long survival time for a patient with metachronous advanced double primary lung and colon adenocarcinoma: A case report

Contact Info

Product

Resources

About